ArticleFrontiers in immunology2025

Pharmacoeconomic evaluation of weight-based vs fixed-dose pembrolizumab for non-small cell lung cancer in China.

Meiyu Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.